ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225
- Jul 25, 2019
- 1 min read
Geneva, Switzerland, July 24, 2019 – Recombinant monoclonal antibody H225, a blocker of JAM-C (Junction Adhesion Molecule C) generates impressive efficacy data in a Mantle Cell Lymphoma animal model.
Comments